Published in Mov Disord on February 13, 2013
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology (2014) 1.59
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord (2015) 1.15
Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations. J Neurol (2014) 0.92
Effects of dopaminergic therapy on locomotor adaptation and adaptive learning in persons with Parkinson's disease. Behav Brain Res (2014) 0.91
Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. Parkinsonism Relat Disord (2015) 0.89
Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's disease. Front Aging Neurosci (2014) 0.87
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol (2016) 0.86
Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. Mov Disord (2015) 0.85
Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease. Eur J Nucl Med Mol Imaging (2014) 0.84
Decreased interhemispheric functional connectivity in subtypes of Parkinson's disease. J Neurol (2015) 0.81
Morphologic changes in the mesolimbic pathway in Parkinson's disease motor subtypes. Parkinsonism Relat Disord (2015) 0.81
Quantitative Susceptibility Mapping in Parkinson's Disease. PLoS One (2016) 0.79
Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes. J Neural Transm (Vienna) (2014) 0.79
Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes. Front Neuroanat (2016) 0.79
Force Variability during Dexterous Manipulation in Individuals with Mild to Moderate Parkinson's Disease. Front Aging Neurosci (2015) 0.79
Balance, Body Motion, and Muscle Activity After High-Volume Short-Term Dance-Based Rehabilitation in Persons With Parkinson Disease: A Pilot Study. J Neurol Phys Ther (2016) 0.78
Two-Year Trajectory of Fall Risk in People With Parkinson Disease: A Latent Class Analysis. Arch Phys Med Rehabil (2015) 0.78
Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics (2015) 0.78
Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Mov Disord (2016) 0.77
Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. J Parkinsons Dis (2015) 0.77
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord (2015) 0.77
Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease. Parkinsons Dis (2016) 0.76
Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. J Parkinsons Dis (2016) 0.76
The contribution of proprioceptive information to postural control in elderly and patients with Parkinson's disease with a history of falls. Front Hum Neurosci (2014) 0.76
Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease. Ann Clin Transl Neurol (2015) 0.76
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol (2016) 0.76
Resting State fMRI Reveals Increased Subthalamic Nucleus and Sensorimotor Cortex Connectivity in Patients with Parkinson's Disease under Medication. Front Aging Neurosci (2017) 0.75
Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Ann Clin Transl Neurol (2016) 0.75
Curved Walking Rehabilitation with a Rotating Treadmill in Patients with Parkinson's Disease: A Proof of Concept. Front Neurol (2017) 0.75
Factors Associated With Ambulatory Activity in De Novo Parkinson Disease. J Neurol Phys Ther (2017) 0.75
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. Ann Clin Transl Neurol (2016) 0.75
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord (2016) 0.75
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord (2017) 0.75
Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry (2016) 0.75
Is PIGD a legitimate motor subtype in Parkinson disease? Ann Clin Transl Neurol (2016) 0.75
Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments. Biomed Eng Online (2016) 0.75
Structural Brain Alterations in Motor Subtypes of Parkinson's Disease: Evidence from Probabilistic Tractography and Shape Analysis. PLoS One (2016) 0.75
Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Mov Disord Clin Pract (2016) 0.75
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. J Mov Disord (2016) 0.75
Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease. PLoS One (2016) 0.75
Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder. Parkinsonism Relat Disord (2017) 0.75
Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study. J Neurol (2017) 0.75
Transcranial sonography image characteristics in different Parkinson's disease subtypes. Neurol Sci (2017) 0.75
Increased neuromuscular consistency in gait and balance after partnered, dance-based rehabilitation in Parkinson's disease. J Neurophysiol (2017) 0.75
Altered Functional Connectivity Density in Subtypes of Parkinson's Disease. Front Hum Neurosci (2017) 0.75
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Frontotemporal dementia in elderly individuals. Arch Neurol (2012) 2.21
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord (2012) 1.99
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
Applying a phase II futility study design to therapeutic stroke trials. Stroke (2005) 1.89
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Acculturation and diabetes among Hispanics: evidence from the 1999-2002 National Health and Nutrition Examination Survey. Public Health Rep (2006) 1.84
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol (2005) 1.67
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol (2005) 1.62
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease? Mov Disord (2013) 1.61
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work (2013) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord (2007) 1.55
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53